MGRM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Monogram Technologies to Zimmer Biomet

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. to Zimmer Biomet for $4.04 per share in cash, along with a contingent value right that could yield up to $12.37 per share if certain milestones are met by 2030 [1][3]. Group 1 - Monogram has agreed to be sold to Zimmer Biomet for an upfront payment of $4.04 per share in cash, plus a non-tradeable contingent value right (CVR) that could provide additional cash based on future milestones [1][3]. - Investors have expressed disappointment regarding the sale price, with comments indicating that the price is perceived as too low [2][4]. - Wohl & Fruchter LLP is examining whether the Monogram Board of Directors acted in the best interests of shareholders and if the sale price is fair [4].